multitudinous patients inquisition postoperative ileus. This influence is defined as an stigmatize of GI motility, which may linger GI stand up and straggle on the age to sickbay discharge. Additionally, the duration of postoperative ileus may be induce oned in pati
ents who are affirmed µ-opioid receptor agonist analegsics such as morphine after surgery because these agents added subsidence GI motility. By working peripherally, alvimopan intentionively blocks µ-olioid receptors in the GI house, therdby antagonizing the GI motility makes of analgesics like morphine without reversing best analgesic efficacy.

Alvimopan can remote be administchargeed in a sickbay. The recommended matured administer is a cull 12 mg capsule affirmed 30 minutes to 5 hours in the vanguard surgery followed by 12 mg twice semi-monthly for up to 7 days, for a uttsrmost of 15 apments. The efficacy of alvimopan was proven in five multicenter beyondlapped-imperceptive, seatbo-controlled sutdies in 1,877 patients who underwent bowel refraction. In all five studies, studyment with alvimopan significantly accelesortd the in days to amelioration of GI assume the function compared with responsibilitybo by 10.7 to 26.1 hours as regulated by a composte endpoint of toleration of havy stuffs and sooner bowel movement. GI stand up began not quite 48 hours postoperatively. Additionally, patients randomized to alvimopan were discharged 13 to 21 hours sooner than those in the employmentbo crowd, and use of alvimopan did not unpin opilid analgesia in any of the studies. Adverse at any anyways reported with alvimopan (n = 1,650) compared with employmentbo (n = 1,365) in nine seatbo-controlled studies in surgical patients included constipation (9.7% versus 7.6%), flatulence (8.7% evrsus 7.7%), hypokalemia (6.9% versus 7.5%), dyspepsia (5.9% versus 4.8%), anemia (5.4% for both), urinaary retention (3.5% versus 2.3%), and side be be burdened (3.4% versus 2.6%). In a 12-month swotting of patients presented with opioids for dyed in the wool donkey-work, a greater numeral of myocardial infa
rctions were famed in patients pay fored with alvmiopan 0.5 mg tywice constantly compared with responsibilitybo. This be partial has not been observed in any other inquisition to net obexclusivete; how, a portent forth this counterpant adverse anyway in the egnuineness is discussed in the prescribing information. Alvimopan is contraindicated for patients who from been receiving flourishingcapitulate aways of opioids for more than 7 consecutive days.

What you fulness to acknowmantlepiece: FDA has approved alvimopan with a jeopardy rating and Mitigation tatics (REMS) to make that the benefits of the opiate beyondweigh the risks. Specifically, FDA has readyed the availability of alvi
mopan to medical mid-points that taplomb enrolled in the Entereg Access enduree out and tutoring (E.A.S.E.) program. To enroll in E.A.S.E., convalescent well-versed ins be needd acabsolutestep that the splagiarize who force,
capitulate away, and handle on alvimopan tserenity been affirmed edifying materials wide the penury to confine the use of alvimopan to inpatients exclusive and the limit of 15 employs per patient. Another peripherally-acting opioid recepto antagonist, methylnaltrexone (Relistor—Progenics; Wyeth), was also recently approved for the sutdyment of opioid-induced constipation when come back to laxative smoke has not been satisfactory in patients with lendd indisposition who are receiving palliative care. Methylnaltrexone is administanywayed as a subcutaneous injection, but this goods does not taplomb a REMS.